University of Virginia School of Medicine scientists have developed an approach to drug development and discovery that could dramatically accelerate the creation of new medicines.
By including AI algorithms as part of routine comprehensive molecular profiling, clinicians can uncover clinically significant misdiagnoses in cases labeled as lung squamous cell carcinoma, influencing treatment decisions and patient outcomes, according to a multi-institutional study.
